Investigational drug · Phase 2
ZT-01
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Type 1 Diabetes Mellitus With Hypoglycemia.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "ZT-01"
First trial start
2023
Jul 28, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ZT-01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 1 Diabetes Mellitus With Hypoglycemia
Approved drugs for the same conditions: Type 1 diabetes · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "ZT-01" as an intervention, largest first.
- A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 DiabetesPivotal-lookingRecruiting
Zucara Therapeutics Inc.Industry
NCT05762107 · 186 participants (planned) · Start Jul 28, 2023 · Primary completion Dec 2026
Drug: Placebo; ZT-01, 7 mg and 2 more · For: Type 1 Diabetes Mellitus With Hypoglycemia
Sites: Birmingham, Alabama; Little Rock, Arkansas; Escondido, California · 46 sites in all
Zucara Therapeutics Inc.Industry
NCT05007977 · 24 participants · Start Jul 8, 2021 · Primary completion Apr 12, 2022
Drug: ZT-01 low dose; ZT-01 high dose and 1 more · For: Type 1 Diabetes; Hypoglycemia
Sites: Toronto, Canada
Newest research
PubMed records naming it or its code names, newest first.
- One Week Exposure to a Somatostatin Receptor 2 Antagonist (SSTR2a) Enhances Glucagon Counterregulation to Insulin-Induced Hypoglycaemia and Does Not Worsen Glycemia in a Male Rat Model of Insulin-Requiring Type 2 Diabetes.
D'Souza NC, Hoffman EG, Atherley SC, et al. · Diabetes Obes Metab 2026
- Effect of somatostatin receptor 2 antagonism on glucagon counterregulation during a hyperinsulinaemic euglycaemic-hypoglycaemic glucose clamp in adult men and women with long-standing type 1 diabetes: a randomised crossover phase 1 study.
Abitbol A, Riddell MC, Peers S, et al. · Diabetologia 2026
- Evaluating the effectiveness of a novel somatostatin receptor 2 antagonist, ZT-01, for hypoglycemia prevention in a rodent model of type 2 diabetes.
D'Souza NC, Aiken JA, Hoffman EG, et al. · Front Pharmacol 2024
- Effects of somatostatin receptor type 2 antagonism during insulin-induced hypoglycaemia in male rats with prediabetes.
Hoffman EG, D'Souza NC, Aiken J, et al. · Diabetes Obes Metab 2023
- ZT-01: A novel somatostatin receptor 2 antagonist for restoring the glucagon response to hypoglycaemia in type 1 diabetes.
Farhat R, Aiken J, D'Souza NC, et al. · Diabetes Obes Metab 2022
- [Breeding on eight strains of Pseudostellaria heterophylla based on phenotypic traits and quality in Guizhou province].
Xiong HX, Zhou T, Jiang WK, et al. · Zhongguo Zhong Yao Za Zhi 2014
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.